Rob Etherington, Clene CEO

Mary­land of­fers loan to Clene de­spite ALS tri­al bumps

Even af­ter Utah-based Clene failed to hit its pri­ma­ry end­points for its ALS drug last year, the state of Mary­land is putting its mon­ey at least be­hind Clene’s man­u­fac­tur­ing fa­cil­i­ty.

The Mary­land Board of Pub­lic Works has fi­nal­ized a $3 mil­lion, 60-month loan fa­cil­i­ty with Clene Nanomed­i­cine. The loan was pro­vid­ed by the state’s Neigh­bor­hood Busi­ness­Works pro­gram with­in the Mary­land De­part­ment of Hous­ing and Com­mu­ni­ty De­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.